Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Abstract

Significant technological advances in radiotherapy have been made in the past few decades. High-precision radiotherapy has recently become popular and is contributing to improvements in the local control of the irradiated target lesions and the reduction of adverse effects. Accordingly, for long-term survival, the importance of systemic cancer control, including at non-irradiated sites, is growing. Toward this challenge, the treatment methods in which anti-PD-1/PD-L1 antibodies that exert systemic effects by restoring anti-tumour immunity are combined with radiotherapy has attracted attention in recent years. Previous studies have reported the activation of anti-tumour immunity by radiotherapy, which simultaneously elevates PD-L1 expression, suggesting a potential for combination therapy. Radiotherapy induces so-called 'immunogenic cell death', which involves cell surface translocation of calreticulin and extracellular release of high-mobility group protein box 1 (HMGB-1) and adenosine-5′-triphosphate (ATP). Furthermore, radiotherapy causes immune activation via MHC class I upregulation and cGAS-STING pathway. In contrast, induction of immunosuppressive lymphocytes and the release of immunosuppressive cytokines and chemokines by radiotherapy contribute to immunosuppressive reactions. In this article, we review immune responses induced by radiotherapy as well as previous reports to support the rationale of combination of radiotherapy and anti-PD-1/PD-L1 antibodies. A number of preclinical and clinical studies have shown the efficacy of radiotherapy combined with immune checkpoint inhibition, hence combination therapy is considered to be an important future strategy for cancer treatment.

A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs

“…Recently, anti-PD-1/PD-L1 antibodies combined with standard chemotherapy or radiation have been intensively conducted in human’s clinical trial because those therapies were reported to enhance the antitumor immune response 38 , 39 . Twenty seven out of 30 cases had received prior therapies including surgery, radiation, systemic chemotherapy, and other immunotherapy before initiation of the present study, and were judged as refractory to those prier therapies when anti-PD-1 antibody therapy started.…”

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

“…These results underline the negative prognostic value of PD-L1 and highlight the importance of lymphocyte-tumor interface. It is known that RT increases the expression of PD-L1 and promotes anti-tumor immunity [93], therefore, it is reasonable to think that, in the era of immunotherapy, the combination of PD-L1 and CD8 expression may have an important predictive response value [94].…”

Wnt/β-catenin Inhibitor ICG-001 Enhances the Antitumor Efficacy of Radiotherapy by Increasing Radiation-induced DNA Damage and Improving Tumor Immune Microenvironment in Hepatocellular Carcinoma

“…The interaction and communication between radioresistance and TME of cancer cells is complicated [26,27]. Basically, the instinct radioresistant property protects cancer cell form death, thus generating less dsDNA and weakening antigen presentation upon radiation [28].…”